{
    "clinical_study": {
        "@rank": "111025", 
        "arm_group": {
            "arm_group_label": "Relestat Ophthalmic Solution 0.05%", 
            "description": "Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice."
        }, 
        "brief_summary": {
            "textblock": "This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and\n      efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who\n      are treated with Relestat as standard of care in clinical practice."
        }, 
        "brief_title": "Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.", 
                        "title": "Relestat Ophthalmic Solution 0.05%"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "745"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "143"
                                            }
                                        }, 
                                        "sub_title": "<20 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "129"
                                            }
                                        }, 
                                        "sub_title": "20 to 29 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "139"
                                            }
                                        }, 
                                        "sub_title": "30 to 39 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "127"
                                            }
                                        }, 
                                        "sub_title": "40 to 49 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "84"
                                            }
                                        }, 
                                        "sub_title": "50 to 59 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "73"
                                            }
                                        }, 
                                        "sub_title": "60 to 69 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "50"
                                            }
                                        }, 
                                        "sub_title": "\u226570 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age, Customized", 
                            "units": "Participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "487"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "258"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }, 
                "population": "The Safety Assessment Population which included all patients who completed the study, was used for the analysis of baseline characteristics."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.", 
                                "title": "Relestat Ophthalmic Solution 0.05%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "745"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0.13"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.", 
                                    "param": "Number", 
                                    "title": "Percentage of Patients Reporting Adverse Events", 
                                    "units": "Percentage of Patients"
                                }
                            ]
                        }, 
                        "population": "Safety Assessment Population: included all patients who completed the study.", 
                        "safety_issue": "No", 
                        "time_frame": "Up to 10 Months", 
                        "title": "Percentage of Patients Reporting Adverse Events", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.", 
                                "title": "Relestat Ophthalmic Solution 0.05%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "741"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.25", 
                                                        "@value": "5.58"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.17", 
                                                        "@value": "-4.06"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at 2 Weeks"
                                            }
                                        ]
                                    }, 
                                    "description": "Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale", 
                                    "units": "Scores on a Scale"
                                }
                            ]
                        }, 
                        "population": "Efficacy Assessment Population: included all patients in the Safety Assessment Population whose data was available for analysis.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 2 Weeks", 
                        "title": "Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.", 
                        "title": "Relestat Ophthalmic Solution 0.05%"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "65", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Protocol Violation"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "37", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lost to Follow-up"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "847", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "745", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "102", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "clinicaltrials@allergan.com", 
                "name_or_title": "Vice President  GSE,", 
                "organization": "Allergan, Inc", 
                "phone": "714-246-4500"
            }
        }, 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Conjunctivitis, Allergic", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in\n             clinical practice.\n\n        Exclusion Criteria:\n\n          -  None."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in\n        clinical practice."
            }
        }, 
        "enrollment": {
            "#text": "847", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "firstreceived_results_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987765", 
            "org_study_id": "198027-A"
        }, 
        "intervention": {
            "arm_group_label": "Relestat Ophthalmic Solution 0.05%", 
            "description": "Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.", 
            "intervention_name": "Relestat Ophthalmic Solution 0.05%", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gangwon-do", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.", 
                "measure": "Percentage of Patients Reporting Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 Months"
            }, 
            {
                "description": "Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.", 
                "measure": "Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 Weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987765"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}